Archive for the ‘Medical Device’ Category
Tuesday, January 10th, 2012
 Star Trek's Mr. Spock with a Tricorder.
We’re already using smartphones that resemble “Star Trek” Communicators. But if you can create a device that could quickly scan a patient and diagnose his ailments like the Tricorder used by Dr. McCoy and other characters on the popular TV series, you could be $10 million richer.
The X PRIZE Foundation, which is trying to solve the world’s Grand Challenges of our time by creating and managing large-scale, global incentivized competitions, has announced a collaboration with Qualcomm Incorporated to design the Tricorder X PRIZE, a $10 million prize to develop a mobile solution that can diagnose patients better than or equal to a panel of board certified physicians.
The X PRIZE Foundation and Qualcomm seeks to achieve this by combining advancements in expert systems and medical point of care data such as wireless sensors, advancements in medical imaging and microfluidics.
The Tricorder X PRIZE aims to incentivize consumer empowerment in healthcare by extending the reach of health information and services to more people. This prize will bring understandable, easily accessible health information and metrics to consumers on their mobile devices, pointing them to earlier actions for care.
Eugene Wesley “Rod” Roddenberry, Jr., son of Star Trek creator, Gene Roddenberry, commented, “It is great to see two amazing organizations — the X PRIZE Foundation and Qualcomm — bring the technology of Star Trek to life and make the Tricorder a reality for people everywhere.”
The X PRIZE Foundation will be collaborating with industry experts and advisors to complete the Tricorder X PRIZE design in 2011. It expects to launch the competition in early 2012.
Tags: Dr. McCoy, Eugene Wesley "Rod" Roddenberry, Gene Roddenberry, Mr. Spock, Qualcomm, Star Trek, Tricorder X Prize, X prize Foundation Posted in Hardware, Medical Device, Mobile, Tech Culture | Comments Off
Wednesday, October 19th, 2011
Venture capitalists invested $6.95 billion in 876 deals in the third quarter of 2011, falling in both dollars and deal volume, according to the MoneyTree Report from PricewaterhouseCoopers LLP (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters.
The software industry saw the highest level of funding and was one of the few to see an increase in dollars invested. Early stage funding deals represented nearly half the total dollars invested, although first time financing deals fell 22 percent.
Quarterly venture capital (VC) investment activity fell 12 percent in terms of dollars and 14 percent in the number of deals compared to the second quarter of 2011 when $7.9 billion was invested in 1,015 deals. For the first three quarters of 2011, venture capitalists invested $21.2 billion into 2,725 deals, representing 20 percent more dollars and three percent more deals as the first three quarters of 2010.
Life sciences industries see marked decline in dollars and deals
The Life Sciences (biotechnology and medical device industries combined) and Clean Technology sectors saw marked decreases in both dollars and number of deals while the Software sector enjoyed its strongest quarter in almost 10 years.
“Challenges in the regulatory environment for Life Sciences companies are prompting VCs to look to other industries to put their money to work for a faster return on their investment as indicated by the notable increase in Software investments,” remarked Tracy T. Lefteroff, global managing partner of the venture capital practice at PwC US.
“Accordingly, over the past two quarters, we’ve seen a clear shift in Life Sciences investments from Seed/Early Stage companies over to more Later Stage companies. VCs are continuing to support the companies in their pipeline but appear to be curbing their investments in new Life Sciences companies.
Despite the dip in Life Sciences and in the overall investment total for Q3, 2011 is still on track to exceed the $23.3 billion invested in all of 2010.” “Given the tremendous impact that venture capital has on company creation, it is easy to forget that our industry is small and highly susceptible to the many market forces presently at work,” said Mark Heesen, president of the NVCA.
“Public policy challenges in the life sciences and clean technology sectors are impacting investment levels this quarter as is the IPO market that basically came to a screeching halt in August.
Venture fundraising levels are the lowest they have been in nearly a decade so it is reasonable to expect investment levels to decline in the coming years. Yet despite the challenges, the industry continues to fund new companies because history has shown us that innovation always prevails and there remains significant promise across all industry sectors for these emerging growth companies.”
Software industry received highest level of funding
The Software industry received the highest level of funding for all industries with $2.0 billion invested during the third quarter of 2011. This level of investment represents a 23 percent increase in dollars, compared to the $1.6 billion invested in the second quarter, and the highest quarterly investment in the sector since the fourth quarter of 2001.
The Software industry also had the most deals completed in Q3 with 263 rounds, which represents a one percent decrease from the 267 rounds completed in the second quarter of 2011. The Biotechnology industry was the second largest sector for dollars invested with $1.1 billion going into 96 deals, falling 18 percent in dollars and 20 percent in deals from the prior quarter.
Medical device industry sees decline
The Medical Devices and Equipment industry also experienced a decline, dropping 18 percent in Q3 to $728 million, while the number of deals declined 21 percent to 74 deals.
Overall, investments in the Life Sciences sector (Biotechnology and Medical Devices) fell 18 percent in dollars and 21 percent in deals, dropping to the second lowest quarterly deal volume since the first quarter of 2005.
To the contrary, Healthcare Services investments surged with $152 million going into 11 deals, a 200 percent increase in dollars and 38 percent increase in deal volume over the second quarter. Investment in Internet-specific companies fell in the third quarter to $1.6 billion going into 231 deals. This level of investment represents a 33 percent decrease in dollars and a 21 percent decrease in deals from the second quarter when $2.4 billion went into 292 deals, a ten-year high.
Internet-specific is a discrete classification assigned to a company with a business model that is fundamentally dependent on the Internet, regardless of the company’s primary industry category.
The Clean Technology sector, which crosses traditional MoneyTree industries and comprises alternative energy, pollution and recycling, power supplies and conservation, saw a 13 percent decrease in dollars to $891 million in Q3 from the second quarter when $1.0 billion was invested.
The number of deals completed in the third quarter also declined nine percent to 80 deals compared with 88 deals in the second quarter Fourteen of the 17 MoneyTree sectors experienced decreases in dollars invested in the third quarter, including:
Telecommunications (49 percent decrease), Semiconductors (44 percent decrease), Consumer Products & Services (51 percent decrease), and Media & Entertainment (11 percent decrease).
Stage of Development Seed stage investments fell 56 percent in dollars and 26 percent in deals with $179 million invested into 89 deals in the third quarter. Early stage investments also fell seven percent in dollars and six percent in deals with $2.0 billion going into 341 deals.
Seed/early stage deals nearly half the total
Seed/Early stage deals accounted for 49 percent of total deal volume in Q3, compared to 48 percent in the second quarter. The average Seed deal in the third quarter was $2.0 million, down from $3.3 million in the second quarter. The average Early stage deal was $5.7 million in Q3, down from $5.8 million in the prior quarter.
Expansion stage dollars increased two percent in the third quarter, with $2.5 billion going into 260 deals. Overall, Expansion stage deals accounted for 30 percent of venture deals in the third quarter, up from 26 percent in the second quarter of 2011. The average Expansion stage deal was $9.6 million, up from $9.2 million in the prior quarter. Investments in Later stage deals decreased 20 percent in dollars and 30 percent in deals to $2.3 billion going into 186 rounds in the third quarter.
Later stage deals accounted for 21 percent of total deal volume in Q3, compared to 26 percent in Q2 when $2.9 billion went into 265 deals. The average Later stage deal in the third quarter was $12.5 million, which increased from $11.0 million in the prior quarter and represents the largest average deal size for Later stage companies since the third quarter of 2001.
First-time financings fell 22 percent
First-Time Financings First-time financing (companies receiving venture capital for the first time) dollars decreased 22 percent and the number of deals fell 18 percent with $1.2 billion going into 269 deals. First-time financings accounted for 17 percent of all dollars and 31 percent of all deals in the third quarter, compared to 20 percent of all dollars and 32 percent of all deals in the second quarter of 2011.
Companies in the Software, Media & Entertainment, and IT services sectors received the most first time rounds in the third quarter. There was a significant decline in the number and dollar level of first time rounds in the Life Sciences sector.
The average first-time deal in the third quarter was $4.5 million, down slightly from $4.7 million in the prior quarter. Seed/Early stage companies received the bulk of first-time investments, garnering 74 percent of the deals. MoneyTree Report results are available online at www.pwcmoneytree.com and www.nvca.org
Tags: dollars and deals decline in Q3, NVCA, PWC, software industry leads VC investment Q3, venture capital report Q3 2011 Posted in Biotech, Energy, entrepreneurship, Hardware, Healthcare, Internet/New Media, Medical Device, Mobile, mobile games, Money, Pharma, Studies, surveys, reports, Telecommunications, Uncategorized, venture capital report | Comments Off
Tuesday, April 19th, 2011
ORLANDO, FL – Orlando-based LensAR has raised $2 million of a targeted $7 million offering, according to a regulatory filing. The company is developing and commercializing laser and 3D imaging technology for refractive cataract surgery.
The company raised $7 million in equity in July 2010 and $7.1 million in August 2009.
Investors in the firm include Aisling Cpaital of New York, and MA-based Extera Partners.
Randy Frey, CEO, writes on the company Web site that “The LensAR approach is to bring the accuracy and precision of lasers into the operating room to replace blades and greatly reduce, if not eliminate, the need for ultrasound power to perform the majority of cataract removals.”
To date, according to the company, the LensAR laser system has been successfully used in well over a hundred eyes outside of the US, and is actively under review with the FDA for approval for use in the United States.
The company disclosed the latest raise in a filing with the U.S. Securities and Exchange Commission.
Contact Tech Journal South Editor and writer Allan Maurer: Allan at TechJournalSouth dot com.
TechJournal South is a TechMedia company. TechMedia presents the annual conferences:
SoutheastVentureConference: www.seventure.org
Internet Summit: www.internetsummit.com
Digital East: www.digitaleast.com
Digital Summit: www.digitalsummit.com
Tags: financing, FL, laser 3D imaging for catarac surgery, LensAR, Orland, SEC Posted in Florida, Healthcare, Medical Device, Money | Comments Off
Tuesday, April 5th, 2011
DULUTH, GA – Solohealth, which has developed self-service health screening and information kiosks, has raised $4 million in a mixed securities offering, according to a regulatory filing.
The company was awarded a $1.2 million National Institutes of Health grant in June last year. Founded in 2007, it previously raised about $2.8 million from private investors.
SoloHealth presented at TechMedia’s 2010 Southeast Venture Conference.
SoloHealth’s Health and Wellness kiosks represent a new approach in publicly available, self-service health-screening. The kiosks are data-centric and use a combination of interactive health screening software and self-reported health information to produce individualized reports for consumers.
The customized reports also provide information on prevention, coupons for relevant products and services as well as doctor referrals to drive consumers to follow-up care and treatment.
SoloHealth’s EyeSite kiosk, which provides free vision screening, is already deployed in high-traffic retail locations like Kroger and Schnucks in seven markets including Atlanta, Birmingham, Houston, St. Louis, Richmond, Madison, WI and Salt Lake City.
Nearly 100 EyeSite kiosks are providing vision screening for more than 400,000 people to-date. Significantly, 25 percent of users reported never previously having had an eye exam.
The company disclosed the funding in a filing with the U.S. Securities and Exchange Commission.
TechJournal South is a TechMedia company. TechMedia presents the annual conferences:
SoutheastVentureConference: www.seventure.org
Internet Summit: www.internetsummit.com
Digital East: www.digitaleast.com
Digital Summit: www.digitalsummit.com
Tags: Duluth, EyeSite kiosks, financing, GA, Healthcare, Medical Device, Solohealth, Southeast Venture Conference Posted in Georgia, Healthcare, Medical Device, Money | Comments Off
Thursday, March 31st, 2011
NEWPORT NEWS, VA – Dilon Technologies Inc., a medical imaging solutions company, has raised $875,000 from a $1.5 million mixed securities offering, according to a regulatory filing.
According to the filing with the U.S. Securities and Exchange Commission, 39 investors purchased securities. The company raised $2.2 million from nearly 200 investors in April 2010.
Dilon Diagnostics designes, makes and sells medical imaging solutions based on cooperative R&D with the U.S. Department of Energy’s Thomas Jefferson National Accelerator and medical universities. Its Dilon 6800 is a high resolution compact gamma camera that images small body parts: breast, thyroid, spot bone scans.
TechJournal South is a TechMedia company. TechMedia presents the annual conferences:
SoutheastVentureConference: www.seventure.org
Internet Summit: www.internetsummit.com
Digital East: www.digitaleast.com
Digital Summit: www.digitalsummit.com
Tags: Dilon Technologies, financing, imaging solutions, Medical Device, Newport News, SEC filings, VA Posted in Medical Device, Money, Potomac, Virginia | Comments Off
Wednesday, March 16th, 2011
DURHAM, NC -Advanced Animal Diagnostics (AAD), a developer of technologies for the rapid diagnosis of farm animal diseases, has closed an $11 million Series B round of equity financing. This investment in AAD represents the largest single investment in research and development to diagnose mastitis, the costliest disease for dairy producers worldwide. The financing was led by Intersouth Partners and included Novartis Venture Funds as well as other private investors.
The company expects this financing to support hiring for key positions, production and manufacturing, and on-farm economic trials of its first product line. The firm is currently seeking cooperators for those on-farm trials.
AAD is a research and development company dedicated to bringing highly accurate, rapid animal diagnostic tests to the farm. The company’s first on-farm product will focus on improving milk production and quality by controlling mastitis, an infection of the milk-producing gland.
Future products will monitor disease states, reproductive, nutritional and overall health status of production animals.
“With this investment, AAD will be able to bring to market a new generation of diagnostics technologies that will revolutionize the way farmers approach animal health, allowing them to detect and diagnose diseases in their animals more quickly and efficiently than ever before,” said Joy Parr Drach, president and CEO of AAD. “We appreciate that our investors recognize the opportunity of investments in agriculture.”
“Food producers are under increasing pressure. The value in AAD’s strong platform of technologies can help them improve animal health and profitability,” said Jimmy Rosen, partner at Intersouth Partners. “We’re excited to support this company and its technology.”
Dr. Simon Wheeler, managing director at Novartis Venture Fund added, “Novartis Venture Fund is confident that with its new technology, AAD will bring significant benefits to the dairy industry and enhance food production worldwide. The investment meets the aim of our fund to provide innovative patient benefit and supports Novartis’s mission to save, prolong and improve animal lives.”
TechJournal South is a TechMedia company. TechMedia presents the annual conferences:
SoutheastVentureConference: www.seventure.org
Internet Summit: www.internetsummit.com
Digital East: www.digitaleast.com
Digital Summit: www.digitalsummit.com
Tags: Advanced Animal Diagnostics, farm animal disease diagnostics, financing, hiring, Intersouth Partners, jobs, Novartis, venture capital Posted in Carolinas, Medical Device, Money, North Carolina | Comments Off
Wednesday, March 16th, 2011
MORRISVILLE, NC – Centice Corp., a company selling technology to improve the verification of dispensed medicines and spot counterfeits, has raised $1.1 million of $1.5 million debt offering, according to a regulatory filing.
The company raised about $1.3 million in equity late in 2010.
That investment followed a $1.82 million equity raise in April. The company disclosed both financings in filings with the US Securities and Exchange Commission.
In 2009, Centice, a Duke University spinout founded in 2004, raised a $6.1 million C round with new investor Fulcrum Financial Group. Other backers include The Aurora Funds Inc., Russian-based S-Group Direct Investments, Innovation Ventures, Novak Biddle Venture Partners, and several individuals. The company raised about $18 million previously through equity and debt.
Centice says its PASS Rx technology is the first and only product that utilizes patented spectroscopy and machine vision sensor technologies to confirm the accuracy of a pharmacy’s dispensed solid dose medications in a matter of seconds. Pharmacy errors in dispensing drugs are all too common and cause as many as 7,000 deaths every year.
The problem is compounded by a national shortage of pharmacists, industry groups say.
Centice technologies have additional applicability beyond just the verification of solid medications in the pharmacy, and the company has plans to develop future products for solid drug identification, liquid medication verification and counterfeit drug detection.
Scott Albert, managing general partner of Centice investor The Aurora Funds, based in the Research Triangle Park, heads the firm as CEO and chair.
TechJournal South is a TechMedia company. TechMedia presents the annual conferences:
SoutheastVentureConference: www.seventure.org
Internet Summit: www.internetsummit.com
Digital East: www.digitaleast.com
Digital Summit: www.digitalsummit.com
Tags: Aurora Funds, Centice, medicine verification, Morrisville, NC, Novak Biddle, pharmacy tech, Scott Albert Posted in Carolinas, Healthcare, Medical Device, Money, North Carolina | Comments Off
Tuesday, March 8th, 2011
RESEARCH TRIANGLE PARK, NC – Bioptigen Inc., a company that has developed in vivo optical imaging systems that enables real-time, noninvasive imaging of internal tissue microstructure, has raised $1.5 million from a single investor, according to a regulatory filing.
Bioptigen is a spin-out of the Duke University Biomedical Engineering Department. Bioptigen was incorporated in North Carolina in August, 2004, to commercialize technologies originating in the laboratories of Professor Joseph Izatt.
The company’s technology is based on the science of Optical Coherence Tomography, an imaging system similar in function to ultrasound, but using low-power light rather than sound waves.
OCT offers resolution 100-times finer than standard ultrasound, suitable for analyzing tissue microstructure with features smaller than 4 micrometer.
Bioptigen sold $542,500 in mixed securities in 2007.
The company disclosed the current raise in a filing with the US Securities and Exchange Commission.
TechJournal South is a TechMedia company. TechMedia presents the annual conferences:
SoutheastVentureConference: www.seventure.org
Internet Summit: www.internetsummit.com
Digital East: www.digitaleast.com
Digital Summit: www.digitalsummit.com
Tags: Biotigen, Duke University, financing, Medical Device, OTC, Research Triangle Park Posted in Biotech, Carolinas, Healthcare, Medical Device, Money, North Carolina | Comments Off
Tuesday, February 8th, 2011
ROANOKE, VA - ELENZA Inc., a company developing the world’s first Electro-active AutoFocal Intraocular Lens, has raised $24 million Series B round of financing from from its original investors, The Carlyle Group, Washington, DC, and Delphi Ventures, Menlo Park, CA,, as well as new investors, the Itochu Corp., Tokyo, Japan and a strategic corporate investor from the ophthalmic industry.
The company says the funds will be used to support the clinical development and technology commercialization of ELENZA’s patented Electro-active AutoFocal Intraocular Lens to address the cataract extraction market and future opportunities associated with the correction of presbyopia. This capital placement is also expected to fund clinical and regulatory activities required to obtain CE mark in Europe and other international markets.
The comany competes in the multi-billion dollar IOL market for the correction of near, intermediate and distance vision. Its Electro-active Accommodating IOLs use a proprietary combination of chemistry, electricity, and integrated-circuitry to create smart optics, which will provide patients with the ability to see more naturally and clearly over a range of vision.
The technology includes an Electro-active switchable optical element that automatically adjusts focusing power electronically, in milliseconds, to maintain constant in focus vision for various working needs and/or light environments. The lens is controlled by a micro-sized power-cell with an expected 50+ year rechargeable cycle life.
Tags: auto-focusing interocular lens, Delphi Ventures, Elenza, financing, Itochu Corp., Medical Device, Roanoke, The Carlyle Group, VA Posted in Healthcare, Medical Device, Money, Potomac, Virginia | Comments Off
Thursday, January 27th, 2011
FORT LAUDERDALE, FL – The medical device space is still one of the hotter investment sectors, particularly in areas that bring sensing and analytics together. OrthoSensor Inc., a company developing intelligent orthopedic implants and sensor-assisted surgery systems, has raised $21 million in Series B financing from Ziegler Meditech Equity Partners and an unnamed strategic investor.
OrthoSensor is developing and commercializing intelligent orthopedic devices that will enable evidence-based orthopedic surgery and remote monitoring of orthopedic implants with the goal of improving patient outcomes and reducing the cost of treating musculoskeletal disease.
OrthoSensor has three product platforms: OrthoSensor Surgical, OrthoSensor Implantables and OrthoSensor Analytics. The first OrthoSensor Surgical products are disposable, sensor-enabled devices that will provide quantitative, intra-operative feedback to surgeons to help ensure the proper balance and alignment of orthopedic implants.
These intelligent devices will allow real time optimization of patients’ specific joint kinematics. Accurate implant placement and soft tissue balance have been shown to extend the life of implants, reduce the incidence of revision surgeries and improve patient function.
“The next wave of innovation in orthopedic surgery is going to be driven by devices that enable surgeons to make real-time, data-driven decisions and help to deliver on the promise of personalized medicine,” commented Eitan Machover, managing partner, Ziegler Meditech Equity Partners.
Tags: financing, FL, Fort Lauderdale, orthopedic medical devices, OrthoSensor, Ziegler Medictech Equity Partners Posted in Florida, Medical Device, Money | 1 Comment »
|
|
|